Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.17 EUR | +0.63% | +1.28% | -32.12% |
Mar. 18 | Biotalys, Novonesis Sign Deal to Advance Biofungicide Candidate Development | MT |
Mar. 18 | Biotalys and Novonesis Announces Manufacturing and Commercialization Partnership for EVOCA NG | CI |
Sales 2024 * | 3M 3.2M | Sales 2025 * | 3M 3.2M | Capitalization | 102M 109M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 34 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 34 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 75 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.77% |
Latest transcript on Biotalys NV
1 day | +0.63% | ||
1 week | +1.28% | ||
Current month | +2.92% | ||
1 month | -5.93% | ||
3 months | -28.92% | ||
6 months | -6.76% | ||
Current year | -32.12% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin R. Helash
CEO | Chief Executive Officer | 59 | Nov. 30 |
Douglas Minder
DFI | Director of Finance/CFO | - | 20-12-31 |
Carlo Boutton
CTO | Chief Tech/Sci/R&D Officer | - | 22-05-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 62 | 12-12-31 | |
Simon Moroney
CHM | Chairman | 65 | 21-03-31 |
Johan Cardoen
BRD | Director/Board Member | 65 | 12-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 3.17 | +0.63% | 7,439 |
24-04-18 | 3.15 | +0.32% | 8,299 |
24-04-17 | 3.14 | +6.80% | 28,316 |
24-04-16 | 2.94 | -8.41% | 28,546 |
24-04-15 | 3.21 | +2.56% | 20,785 |
Real-time Euronext Bruxelles, April 19, 2024 at 11:35 am EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-32.12% | 108M | |
-4.04% | 7.15B | |
+10.44% | 3.17B | |
+12.35% | 864M | |
-5.04% | 348M | |
+18.64% | 305M |
- Stock Market
- Equities
- BTLS Stock